Mirae Asset TIGER Samsung Group ETF (138520)

Overview

Keymed Biosciences Inc. is a biotechnology entity focused on the pioneering development of biological therapies aimed at the treatment of diseases across autoimmunity and oncology spectrums. Renowned for its progressive research and development endeavors, the company specifically targets a myriad of conditions with its innovative product pipeline. Initially established as 2Health Biosciences, Inc., it underwent a rebranding to better represent its mission and scope in the bioscience field. Founded in 2016, Keymed Biosciences is strategically headquartered in Chengdu within the People's Republic of China, positioning it at the heart of China's booming biotech industry.

Products and Services

CM310: This lead product candidate demonstrates Keymed Biosciences’ forefront in innovative therapeutic solutions, primarily designed for the treatment of moderate to severe atopic dermatitis (AD). Its versatility extends to addressing asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD), showcasing the company’s dedication to wide-ranging healthcare solutions.

CM326: In its commitment to combating severe AD, CRSwNP, asthma, and COPD, Keymed Biosciences is also developing CM326. This monoclonal antibody specifically targets thymic stromal lymphopoietin, further emphasizing the company’s focused approach on autoimmune and pulmonary conditions.

CMG901: Diving into the realm of oncology, CMG901 is being developed to tackle solid tumors, alongside gastric and gastroesophageal cancers. This initiative underscores Keymed Biosciences’ commitment to expanding its research and development efforts beyond autoimmune diseases into critical areas of cancer treatment.

CM313: This humanized monoclonal antibody is part of the company’s arsenal against hematological malignancies including relapsed or refractory multiple myeloma and lymphoma. Furthermore, CM313 shows promise in the treatment of systemic lupus erythematosus, demonstrating Keymed Biosciences’ versatile approach to both cancer and autoimmune diseases.

CM338: As an antagonist antibody against mannose-binding lectin-associated serine protease-2, CM338 represents another facet of the company’s diverse product pipeline, focusing on a novel target within the immune reaction cascade.

CM355: Dedicated to addressing relapsed or refractory non-Hodgkin's lymphoma, CM355 is part of Keymed Biosciences’ targeted efforts in the realm of blood cancers, highlighting their commitment to providing options for hard-to-treat cancers.

CM336: Specifically aimed at multiple myeloma, CM336 targets another niche within the hematological malignancy sector, underlining the company’s dedication to addressing various forms of cancer with precision.

CM350: Developed for the treatment of solid tumors, CM350 adds to the company’s robust offerings in oncology, showcasing its committed research and development efforts towards combating cancer in all its forms.

CM369: This anti-CC chemokine receptor 8 monoclonal antibody is yet another testament to Keymed Biosciences’ innovative approach within its product portfolio, targeting specific mechanisms within the immune system to treat diseases.